Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 58% below its 5-year average of 0.03, near the high end of its 5-year range (-0.70–0.14).
As of the fiscal period ended Tuesday, June 30, 2026. 45.94% below its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.04
DEBT TO EQUITY RATIO AVG 5Y
0.03
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-45.94%
CURRENT VS 3Y AVG
-66.16%
CURRENT VS 5Y AVG
-58.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-88.27%
vs the sector median at left
Bullfrog AI Holdings, Inc. Common Stock
Market Cap
$12.78M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$12.58M
Debt to Equity Ratio
N/A
TTM Avg
1.01
3Y Avg
1.00
5Y Avg
0.90
Market Cap
$12.48M
Debt to Equity Ratio
N/A
TTM Avg
0.93
3Y Avg
0.49
5Y Avg
0.33
Market Cap
$12.44M
Debt to Equity Ratio
N/A
TTM Avg
3.67
3Y Avg
2.17
5Y Avg
1.48
Market Cap
$13.11M
Debt to Equity Ratio
0.00
TTM Avg
0.85
3Y Avg
0.52
5Y Avg
0.35
Market Cap
$13.20M
Debt to Equity Ratio
0.11
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$13.30M
Debt to Equity Ratio
0.29
TTM Avg
0.66
3Y Avg
0.36
5Y Avg
0.25
Market Cap
$12.17M
Debt to Equity Ratio
N/A
TTM Avg
6.01
3Y Avg
3.01
5Y Avg
2.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $12.78M | 0.01 | 0.02 | 0.04 | 0.03 |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | N/A | 1.01 | 1.00 | 0.90 |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A | 0.93 | 0.49 | 0.33 |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | N/A | 3.67 | 2.17 | 1.48 |
| Passage Bio, Inc. (PASG)vs › | $13.11M | 0.00 | 0.85 | 0.52 | 0.35 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | 0.11 | 0.01 | 0.01 | 0.02 |
| Optimi Health Corp. (OPTH)vs › | $13.30M | 0.29 | 0.66 | 0.36 | 0.25 |
| IN8bio, Inc. (INAB)vs › | $13.33M | 0.12 | 0.22 | 0.23 | 0.16 |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | 6.01 | 3.01 | 2.01 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.06M | 0.05 | 0.04 | 0.04 | 0.03 |
Debt/Equity
0.01
Current Ratio
10.57
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.03 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.05 |
| 2025-03-31 | 0.05 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.04 |
| 2024-06-30 | 0.06 |
| 2024-03-31 | 0.07 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.06 |
| 2023-06-30 | 0.09 |
| 2023-03-31 | 0.14 |
| 2022-12-31 | -0.52 |
| 2022-09-30 | -0.61 |
| 2022-06-30 | -0.70 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | -0.58 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
